- Raw materials
- Gastrointestinal Agents
- Ipragliflozin
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Ipragliflozin API Manufacturers & Suppliers
2 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Employees: 50
All certificates
Employees: 10+
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Ipragliflozin | CAS No: 761423-87-4 | GMP-certified suppliers
A medication that supports glycemic control in Type 2 Diabetes Mellitus by lowering blood glucose through sodium-glucose cotransporter 2 (SGLT2) inhibition.
Therapeutic categories
Product Snapshot
- Ipragliflozin is an oral small molecule formulation
- It is primarily developed for the management of type 2 diabetes mellitus
- The compound is currently in the investigational phase without FDA or EMA approval
Clinical Overview
Pharmacologically, ipragliflozin belongs to the class of sodium-glucose cotransporter 2 (SGLT2) inhibitors. SGLT2 is a protein expressed in the proximal tubules of the kidneys, responsible for reabsorbing the majority of filtered glucose back into the bloodstream. By inhibiting SGLT2, ipragliflozin reduces glucose reabsorption, promoting glycosuria and thereby lowering plasma glucose levels. This mechanism is independent of insulin secretion, offering a distinct approach to glycemic control compared to other antidiabetic agents.
Key pharmacokinetic parameters such as absorption, distribution, metabolism, and excretion (ADME) for ipragliflozin have been studied to some extent in clinical investigations; however, detailed data on these parameters remain limited due to its investigational status.
Safety and toxicity profiles are also under evaluation. As a member of the SGLT2 inhibitor class, potential adverse effects may include urinary tract infections and volume depletion; however, specific safety data for ipragliflozin are not fully established. Its clinical efficacy and safety continue to be assessed in ongoing studies.
Ipragliflozin is not currently approved for commercial use and is categorized under investigational drugs. Notable global brands or marketed products containing ipragliflozin have not been established.
From a formulation and sourcing perspective, procurement of ipragliflozin API requires careful attention to quality and purity standards consistent with regulatory guidelines for investigational compounds. Reliable supply chains and thorough characterization of physicochemical properties are essential for ensuring batch-to-batch consistency and suitability for further pharmaceutical development.
Identification & chemistry
| Generic name | Ipragliflozin |
|---|---|
| Molecule type | Small molecule |
| CAS | 761423-87-4 |
| UNII | 3N2N8OOR7X |
| DrugBank ID | DB11698 |
Formulation & handling
- Ipragliflozin is a small molecule intended for oral administration with low water solubility, requiring formulation strategies to enhance bioavailability.
- Being a phenolic glycoside, it may exhibit sensitivity to hydrolysis under certain pH conditions, necessitating pH control during formulation and storage.
- LogP value indicates moderate lipophilicity, suggesting absorption could be influenced by food intake and lipid-based formulation approaches may be beneficial.
Regulatory status
Ipragliflozin is a type of Gastrointestinal Agents
Gastrointestinal Agents belong to the pharmaceutical API category that focuses on treating disorders and ailments related to the digestive system. These agents play a crucial role in addressing various gastrointestinal conditions, such as acid reflux, ulcers, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD).
One of the key types of gastrointestinal agents is proton pump inhibitors (PPIs), which work by reducing the production of stomach acid. PPIs help in treating conditions like gastroesophageal reflux disease (GERD) and peptic ulcers. Another essential class of agents is antacids, which neutralize excessive stomach acid, providing relief from heartburn and indigestion.
Gastrointestinal agents also include antispasmodics that alleviate abdominal cramps and spasms associated with conditions like IBS. These drugs work by relaxing the smooth muscles of the digestive tract. Additionally, there are drugs categorized as laxatives that aid in relieving constipation by promoting bowel movements.
Moreover, certain gastrointestinal agents act as antiemetics, effectively reducing nausea and vomiting. These drugs are particularly useful for patients undergoing chemotherapy or experiencing motion sickness.
Pharmaceutical companies develop and manufacture a wide range of gastrointestinal agents in various forms, including tablets, capsules, suspensions, and injections. These agents are typically formulated using active pharmaceutical ingredients (APIs) and other excipients to ensure their efficacy and safety.
In conclusion, gastrointestinal agents form a vital category of pharmaceutical APIs, providing relief from digestive disorders and improving overall gastrointestinal health. The availability of diverse agents catering to different conditions ensures that patients can receive targeted treatment for their specific gastrointestinal needs.
Ipragliflozin API manufacturers & distributors
Compare qualified Ipragliflozin API suppliers worldwide. We currently have 2 companies offering Ipragliflozin API, with manufacturing taking place in 2 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Apino Pharma Co., Ltd. | Producer | China | China | BSE/TSE, cDMF, CoA, GMP, MSDS | 229 products |
| AXXO GmbH | Distributor | Germany | World | CoA, GMP, GDP, MSDS, USDMF | 243 products |
When sending a request, specify which Ipragliflozin API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Ipragliflozin API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
